Director, Generative AI for Protein Design & Biotherapeutics

BioSpace; San Diego (CA); On-site; USD 194,000 - 339,000; Full time

Benefits offered by this job

401(k) plan

Medical, dental, vision benefits

Vacation and time-off

Job summary

Lilly Biotechnology Center in San Diego seeks a Director of AI/ML to lead generative foundation models for biotherapeutics. You will guide end-to-end model development, train across architectures, and direct a team of researchers and engineers while collaborating with wet-lab scientists.

Role emphasizes scientific leadership, experimental validation, and scaling platforms like LillyPod to accelerate de novo design of antibodies and other biotherapeutics.

Qualifications

• Ph.D. in computer science, mathematics, physics, computational biology, or a related quantitative field, with 3+ years of relevant research experience following the Ph.D. (or an M.S. with 6+ years).
• First-author or equivalently attributable contribution to structure-based generative model; end-to-end project experience.
• Experience training deep learning models on multi-node infrastructure; strong Python and PyTorch.

Responsibilities

• Lead generative AI and protein foundation model development, driving state-of-the-art methods for representation learning, design, and multimodal biology.
• Set training strategy and curricula for models across architecture choices and evaluation.
• Design training infrastructure and scale LIllyPod capacity with the ML team.

Skills

Generative AI

Protein design

Deep learning

PyTorch

Multi-node training

Education

PhD in CS/Math/Physics/Computational Biology

Tools

LillyPod

Python

Job description

Lilly Biotechnology Center in San Diego seeks a Director of AI/ML to lead generative foundation models for biotherapeutics. You will guide end-to-end model development, train across architectures, and direct a team of researchers and engineers while collaborating with wet-lab scientists.

Role emphasizes scientific leadership, experimental validation, and scaling platforms like LillyPod to accelerate de novo design of antibodies and other biotherapeutics.